PolyPid Ltd. (PYPD): Price and Financial Metrics
PYPD Price/Volume Stats
| Current price | $4.95 | 52-week high | $38.70 |
| Prev. close | $4.70 | 52-week low | $3.57 |
| Day low | $4.42 | Volume | 5,800 |
| Day high | $4.99 | Avg. volume | 6,908 |
| 50-day MA | $4.35 | Dividend yield | N/A |
| 200-day MA | $10.72 | Market Cap | 3.22M |
PYPD Stock Price Chart Interactive Chart >
PolyPid Ltd. (PYPD) Company Bio
PolyPid Ltd. is a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes. The company was founded by Noam Emanuel in 2008 and is headquartered in Petach Tikva, Israel.
Latest PYPD News From Around the Web
Below are the latest news stories about POLYPID LTD that investors may wish to consider to help them evaluate PYPD as an investment opportunity.
PolyPid Ltd. (NASDAQ:PYPD) Q3 2023 Earnings Call TranscriptPolyPid Ltd. (NASDAQ:PYPD) Q3 2023 Earnings Call Transcript November 12, 2023 Operator: Thank you all for participating in PolyPid’s third quarter 2023 earnings conference call. Joining me on the call today will be Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid; Jonny Missulawin, PolyPid’s Chief Financial Officer; and Ori Warshavsky, Chief Operating Officer of PolyPid. […] |
PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsTotal of 20 Centers Currently Open with Approximately 40 Expected by End of 2023 in SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Completed Production and Release of Three Process Validation Batches of D-PLEX100 Successful Completion of Good Manufacturing Practice Audit of Company’s Manufacturing Facility Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Nov. 08, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq |
PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of DirectorsBiopharmaceutical Industry Veteran Nurit Tweezer-Zaks, M.D., M.B.A. Appointed to Board Following Retirement of Anat Tsour SegalPETACH TIKVA, Israel, Nov. 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Nurit Tweezer-Zaks, M.D., M.B.A, to its Board of Directors, effective November 6, 2023, following the retirement of Anat Tsour Segal. Dr. Tweezer-Zaks is a |
PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023PETACH TIKVA, Israel, Nov. 01, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 8, 2023. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business ope |
PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price RulePETACH TIKVA, Israel, Oct. 11, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a written notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities, including the Company's ordinary shares |
PYPD Price Returns
| 1-mo | 22.22% |
| 3-mo | N/A |
| 6-mo | -61.18% |
| 1-year | -80.12% |
| 3-year | -98.43% |
| 5-year | N/A |
| YTD | -76.34% |
| 2022 | -87.85% |
| 2021 | -42.02% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...